The new plant will allow the company to execute end-to-end clinical- and commercial-stage production of its mRNA medicines.

Two of the biggest political issues of the year are immigration and health care. Here’s a look at some recent fact checks of ...

Revaccination with mRNA-1345 against RSV at 12 months was noninferior to primary vaccination among adults aged 50 years and older.

Analysts also weigh in on Chesapeake Utilities, Halozyme Therapeutics, Sea Ltd., and Roper Technologies. Trump reverses on tariffs for some imports, Bitcoin falls on details of strategic reserve, ...

Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March ...

Delaware says COVID-19 vaccines are available at state clinics, regardless of insurance status. But only 2 clinics carried ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

Q2 2026 Earnings Call Transcript November 10, 2025 Immunovant, Inc. misses on earnings expectations. Reported EPS is ...

Q2 2026 Earnings Call Transcript November 10, 2025 Roivant Sciences Ltd. beats earnings expectations. Reported EPS is ...

Background Immunogenicity to SARS-CoV-2 vaccination in patients with SLE varies by vaccine type and immune-modulating therapy. However, data in Southeast Asian populations, especially among Thai ...

A new lipid nanoparticle could make mRNA vaccines more powerful and potentially lower the cost per vaccine dose.